Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dendritic Cell Vaccination in Metastatic Endometrial Cancer
NCT04212377Phase 2Completed
- Sponsor
- Radboud University Medical Center
- Start
- Apr 2019
- Primary completion
- Mar 2021
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in endometrial cancer (EC), sponsored by Radboud University Medical Center. Primary endpoint: Immunologic efficacy of tumor-peptide loaded nDC at 1 year. Started Apr 2019; status: completed.
02
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT04212377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04212377.